ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformati… Read more
ORIENTBIO Inc. (002630) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.001x
Based on the latest financial reports, ORIENTBIO Inc. (002630) has a cash flow conversion efficiency ratio of 0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩99.11 Million) by net assets (₩69.62 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ORIENTBIO Inc. - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how ORIENTBIO Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ORIENTBIO Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ORIENTBIO Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spring Valley Acquisition Corp. II Class A Ordinary Shares
NASDAQ:SVII
|
-0.031x |
|
Island Pharmaceuticals Ltd
AU:ILA
|
-0.237x |
|
KB No.2 Special Purpose Acq
KQ:192250
|
-0.002x |
|
Gowing Bros Ltd
AU:GOW
|
-0.003x |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
0.079x |
|
Revivegen Co., Ltd.
TWO:7578
|
0.014x |
|
Bumyang Construction Co Ltd
KO:002410
|
1.569x |
|
Asri Karya Lestari Tbk.
JK:ASLI
|
-0.088x |
Annual Cash Flow Conversion Efficiency for ORIENTBIO Inc. (2007–2025)
The table below shows the annual cash flow conversion efficiency of ORIENTBIO Inc. from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₩71.85 Billion | ₩752.29 Million | 0.010x | -76.28% |
| 2024-03-31 | ₩85.10 Billion | ₩3.76 Billion | 0.044x | +171.70% |
| 2023-03-31 | ₩71.39 Billion | ₩1.16 Billion | 0.016x | -42.52% |
| 2022-03-31 | ₩83.19 Billion | ₩2.35 Billion | 0.028x | -84.30% |
| 2021-03-31 | ₩48.55 Billion | ₩8.74 Billion | 0.180x | +339.61% |
| 2020-03-31 | ₩51.96 Billion | ₩-3.90 Billion | -0.075x | +59.21% |
| 2019-03-31 | ₩62.65 Billion | ₩-11.54 Billion | -0.184x | -648.68% |
| 2018-03-31 | ₩79.92 Billion | ₩-1.97 Billion | -0.025x | +52.82% |
| 2017-03-31 | ₩97.94 Billion | ₩-5.11 Billion | -0.052x | -621.81% |
| 2016-03-31 | ₩91.29 Billion | ₩912.43 Million | 0.010x | -58.01% |
| 2015-03-31 | ₩67.35 Billion | ₩1.60 Billion | 0.024x | -32.14% |
| 2014-03-31 | ₩61.85 Billion | ₩2.17 Billion | 0.035x | -57.12% |
| 2013-03-31 | ₩62.29 Billion | ₩5.09 Billion | 0.082x | +71.95% |
| 2011-03-31 | ₩65.49 Billion | ₩3.11 Billion | 0.048x | -68.59% |
| 2010-03-31 | ₩61.77 Billion | ₩9.35 Billion | 0.151x | +347.50% |
| 2007-03-31 | ₩44.86 Billion | ₩1.52 Billion | 0.034x | -- |